{"groups":[{"description":"Patients receive fludarabine IV on days -5 to -2 and melphalan IV on days -3 to -2, then undergo stem cell transplantation on day 0. Patients receive cyclophosphamide on days 3 and 4, tacrolimus PO BID or IV starting on day 5, and mycophenolate mofetil IV or PO TID on days 5 to 35. Patients also receive daratumumab IV starting between days 90-150 for up to 1 year. Treatment continues in the absence of disease progression or unacceptable toxicity.\n\nAllogeneic Hematopoietic Stem Cell Transplantation: Undergo allogeneic hematopoietic stem cell transplantation\n\nCyclophosphamide: Given IV\n\nDaratumumab: Given IV\n\nFludarabine: Given IV\n\nMelphalan: Given IV\n\nMycophenolate Mofetil: Given IV or PO\n\nTacrolimus: Given PO or IV","id":"FG000","title":"Treatment (Conditioning Regimen, Stem Cell Transplant)"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"1"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"1"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}